NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Controlled Substances Prescribing & Dispensing; Comments to DOJ & DEA on "Ensuring Lawful Governance and Implementing the Presidents 'Department of Government Efficiency' Deregulatory Initiative"; Comments to DEA on "Special Registrations for Telemedicine and Limited State Telemedicine Registrations [Docket No. DEA-407]"

S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S. 927, the Protecting Pharmacies in Medicaid Act; the Equitable Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)'

H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;

S.587/1301, The Death Tax Repeal Act;

S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025;

TRICARE Pharmacy Network Oversight & Changes;

H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;

Comments to HHS on "HIPAA Security Rule To Strengthen the Cybersecurity of Electronic Protected Health Information [HHS-OCR-0945-AA22]";

Comments to CBP on "June 14, 2024, Internal Advice Letter H283420";

Comments to the White House on the Corporate Transparency Act implementations (NDAA; P.L.116-283);